Y-mAbs push­es back re-sub­mis­sion of its neu­rob­las­toma BLA to end of 2021

Y-mAbs Ther­a­peu­tics on Wednes­day again ad­just­ed its time­line for re-sub­mit­ting its neu­rob­las­toma drug om­bur­tam­ab to the FDA, say­ing the sub­mis­sion won’t like­ly hap­pen un­til the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER